Stockscreener 앱 받기
4.33
2.03%
-0.10
시간 외 거래:
4.33
Acelyrin Inc 주식(SLRN)의 최신 뉴스
HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey
TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada
Acelyrin discloses ValenzaBio acquisition financials - Investing.com India
TD Cowen maintains Buy rating on Acelyrin shares - Investing.com
T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com
Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada
ACELYRIN, INC. Advances Key Drug Developments - TipRanks
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times
ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan
(SLRN) Investment Analysis and Advice - Stock Traders Daily
Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times
ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
1.07%
3.56%
자본화:
|
볼륨(24시간):